Cue Biopharma (CUE) Valuation & Financial Model
Interactive Discounted Cash Flow (DCF) model for Cue Biopharma (US:CUE), trading at 30.40. In 2025, Cue Biopharma generated $27.47 Million in revenue and -$21.86 Million in free cash flow. Explore projected intrinsic value assumptions based on institutional-grade macro metrics.
Valuation Methodology & Recent Performance
The financial model for Cue Biopharma is calculated using an institutional discounted cash flow (DCF) engine utilizing recent operational metrics:
- Current Price: 30.40
- Recent Revenue (2025): $27.47 Million
- Free Cash Flow (2025): -$21.86 Million
- Discount Rate (WACC): Derived using the Risk-Free Rate (e.g., 10Y Gov Bond) plus an Equity Risk Premium based on market volatility and stock price variance.
- Terminal Value: Projected using a perpetual growth model bounded by long-term macroeconomic estimates.